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Available online 17 December 2015von Willebrand disease (VWD) is reportedly the most common bleeding disorder and arises from deﬁciency
and/or defects of vonWillebrand factor (VWF). Laboratory diagnosis and typing of VWDhas important manage-
ment implications and requires a wide range of tests, including VWF antigen (VWF:Ag) and various activities, in-
volving differential identiﬁcation of qualitative vs quantitative VWF defects. We have assessed a new hemostasis
instrument, the chemiluminescent assay based ACL AcuStar™, and an associated HemosIL AcuStar three test
panel comprising VWF:Ag, VWF ristocetin cofactor (VWF:RCo) andVWFcollagen binding (VWF:CB) (Instrumen-
tation Laboratory, Bedford,Ma. USA) for ability to identify VWD, to help provisionally type VWD, and for potential
use in therapy monitoring. This test system was compared to previously evaluated and validated test systems
including VWF:RCo on CS-5100 and BCS analyzers, the new Siemens INNOVANCE assay (VWF Ac) on CS-5100,
and VWF:Ag and VWF:CB assays performed by automated ELISA. We employed a large total sample test set
(n = 535) comprising plasma and platelet-lysate samples from individuals with and without VWD, some on
treatment, normal plasmas, and normal and pathological controls.We also evaluated desmopressin (DDAVP) re-
sponsiveness, plus differential sensitivity to reduction in high molecular weight (HMW) VWF. The chemilumi-
nescent test panel (VWF:Ag, VWF:RCo, VWF:CB) showed good comparability to similar assays performed by
alternate methods, and broadly similar data for identiﬁcation of VWD, provisional VWD type identiﬁcation,
DDAVP and VWD therapy, and HMW VWF sensitivity, although some notable differences were evident. The
chemiluminescent system showed best low level VWF sensitivity, and lowest inter-assay variability, compared
to all other systems. In conclusion, we have validated theACL AcuStar and the chemiluminescent HemosIL
AcuStar VWF test panel for use in VWD diagnostics, and have identiﬁed some favorable characteristics that
may improve the future diagnosis of VWD.
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vonWillebrand disease (VWD) is reportedly themost common con-
genital bleeding disorder and arises from deﬁciency and/or defects of
von Willebrand factor (VWF), an adhesive plasma protein essential for
effective primary haemostasis [1,2]. Clinical identiﬁcation, diagnosis
and typing of VWDare supported by laboratory testing, but this remainsnzyme linked immunosorbent
HMW, high molecular weight
illebrand disease; VWF, von
assay); VWF:Ag, VWF antigen;
istocetin cofactor (assay).
y, Institute of Clinical Pathology
ead Hospital, Westmead, NSW
u (E.J. Favaloro).
r Ltd. This is an open access article uimperfect for many reasons. First, VWD is extremely heterogeneous, as
evidenced by the fact that VWF performsmany adhesive functions that
enables effective capture and localization of platelets and factor VIII
(FVIII) to damaged vasculature, to facilitate both primary and secondary
hemostasis and arrest bleeding. VWF accomplishes this role because it
can bind to platelets (via several receptors, butmost notable glycoprotein
Ib (GPIb)), sub-endothelial matrix components (most notably collagen),
and FVIII (thereby preserving its function) [3]. Therefore, defects may
occur anywhere within VWF, leading to a wide variety of clinical and
laboratory phenotypes. Second, the laboratory tests used to aid identiﬁca-
tion, diagnosis and typing of VWD are very heterogeneous inmethodolo-
gy and diagnostic efﬁcacy. These tests are also imperfect, reﬂecting
different procedures of varied sensitivity to VWF level and activity, as
well as other limitations including poor reproducibility (or high assay
variability), poor sensitivity to low levels of VWF, and variable sensitivity
to high molecular weight (HMW) forms of VWF [4–8].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of VWF test methods comparatively evaluated in this study.
VWF assay Description
VWF:Ag • Assessment of VWF protein level using an ‘antigen’ assay.
• Historically performed by manual ELISA.
• Reference assay performed in this study by automated ELISA
using an ELISA workstation (Best 2000).
• Comparator assay was an automated chemiluminescent based
assay using an AcuStar.
VWF:RCo • Assessment of VWF activity level utilizing ristocetin and
(usually) an ‘agglutination’ assay.
• Historically performed by agglutination using an aggregometer
(originally) or BSC instrument (from 2008).
• Reference assay performed in this study by automated
agglutination assay using a CS-5100 instrument.
• Comparator assays were automated chemiluminescent based
VWF:RCo assay using an AcuStar and Innovance VWF Ac assay
on CS5100 (see below).
VWF:CB • Assessment of VWF activity level utilizing collagen.
• Historically performed by manual ELISA.
• Reference assay performed in this study by automated ELISA
using an ELISA workstation (Best 2000).
• Comparator assay was automated chemiluminescent based
assay using an AcuStar.
VWF Ac • Siemens INNOVANCE VWF ‘activity’ assay.
• Assessment of VWF activity level utilizing a direct
VWF-Glycoprotein Ib binding method.
• The system employs two gain of function Glycoprotein
Ib mutations within a recombinant molecule that facilitates
VWF binding.
• Performed in this study by automated LIA using a CS-5100.
Abbreviations: ELISA, enzyme linked immunosorbant assay; LIA, latex-particle immunoas-
say; VWF, von Willebrand factor; Ag, antigen; RCo, ristocetin cofactor; CB, collagen bind-
ing; Ac, activity.
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Thrombosis and Haemostasis (ISTH) identiﬁes six different types of
VWD [9]. For cases reﬂecting a minor quantitative deﬁciency of
VWF but without a formal diagnosis of VWD, the concept of ‘low VWF’
as a risk factor for bleeding has alternatively been proposed [10].
Quantitative VWD defects are identiﬁed within type 1 (representing a
partial deﬁciency of VWF), and type 3 (representing ‘complete’deﬁcien-
cy of VWF). In type 1 VWD, the VWF produced in lower amount is ‘func-
tionally normal’. Qualitative VWF defects are characterized within type
2 VWD, which actually represents a very heterogeneous group, com-
prising (i) 2A VWD (loss of HMW VWF), (ii) 2B VWD (enhanced func-
tional binding of VWF that leads to loss of HMW VWF and typically
mild thrombocytopenia), (iii) 2N VWD (loss of VWF-FVIII binding),
and (iv) 2M VWF (VWF dysfunction not associated with loss of
HMW VWF).
The proper identiﬁcation of VWD and differentiation of VWD type is
important for therapeutic management [6,11]. In normal laboratory
practice, identiﬁcation of VWD and differentiation of type can be deter-
mined by laboratory testing encompassing a broad panel of different
validated tests [1,2,4–10]. The majority of laboratories perform FVIII co-
agulant (FVIII:C) and VWF antigen (VWF:Ag) [1,5], which respectively
measure levels of FVIII activity and VWF protein, the latter most com-
monly using either ELISA (enzyme linked immunosorbent assay) or
LIA (latex-immuno-assay) technologies. VWF ‘activity’ can be assessed
by a wide variety of methodologies, including ristocetin cofactor
(VWF:RCo), collagen binding (VWF:CB) and newer direct GPIb binding
assays (e.g., Siemens INNOVANCE VWF Ac) [8,12–15]. Which assays,
and how many of these laboratories use as a diagnostic test panel, and
what methodology laboratories employ within each individual assay,
strongly impacts the accuracy of VWD identiﬁcation, diagnosis and typ-
ing [5,8]. VWF:RCo represents the most commonly performed activity
based test [1,2,4–10], usually by platelet agglutination assay using
aggregometry or automated methods with modern hemostasis instru-
ments, and sometimes by LIA technology [8]. Direct GPIb binding assays
provide similar values to VWF:RCo in published studies [8,12–15].
VWF:CB, although typically performed by fewer laboratories, is none-
theless an important activity assay, usually performed by ELISA [1,2,
4–10], and whose omission will compromise VWD identiﬁcation, diag-
nosis and typing [5,8].
Moreover, laboratories and clinicians also need to deal with many
pre-analytical variables affecting laboratory test results [16], as well as
signiﬁcant intra-patient variability in test results, including that VWF
and FVIII are acute phase proteins that increase at times of stress and
also during pregnancy [17]. These considerations further challenge di-
agnosis, since a normal test result does not always exclude VWD
(might be acute phase or pregnancy increase in VWF, or type 2 VWD
with normal VWF:Ag) and an abnormal test result does not always con-
ﬁrm VWD (could be one of many pre-analytical events).
In the current study, we have evaluated a fairly new instrument in
the hemostasis laboratory armamentarium, the ACL AcuStar™, which
employees chemiluminescent technology, for its ability to identify
VWD, to help type VWD, and for potential use in therapy monitoring.
We have used a three VWF test panel on this instrument, namely
HemosIL AcuStar VWF:Ag, HemosIL AcuStar VWF:RCo and HemosIL
AcuStar VWF:CB, and compared ﬁndings to previously evaluated and
validated VWF test systems, employing a large total sample test set
(n= 535) comprising a variety of patient, normal and control material.
This is the ﬁrst such study to include an evaluation of such a three test
system on a single platform.2. Methods
2.1. Assays and instrumentation
The tests evaluated in this study are summarized in Table 1.2.2. Reference and historical methods
FVIII:Cwas assessed for patient samples as part of their original anal-
ysis within our standard VWD diagnostic test panel, using a one stage
clot-based assay on either a Behring BCS or (more recently) CS-5100 an-
alyzers (both from Siemens Healthcare, Marburg, Germany) and Sie-
mens reagents, but has not otherwise been formally assessed in the
current report. Our standard VWF:Ag was performed as an in house
sandwich ELISA assay, essentially as previously extensively reported
by our laboratory (refer to [1,7,8,12] as key references), but now
performed on a BioKit BEST 2000 ELISA workstation (Biokit, Lliçà
d'Amunt, Barcelona, Spain), using polyclonal antibodies from Dako
(Glostrup, Denmark; rabbit anti-human VWF; catalogue no. A0082)
for coating 96-well plates (Linbro Titertek EIA plate; ICN Biomedicals,
Aurora, OH, USA) and Dako horse radish peroxidase labeled rabbit
anti-humanVWF (catalogue no. P0226), for VWFdetection. Historically,
a similar approach was used to perform manual/semi-automated
ELISAs. Our current standard VWF:CB was performed in parallel with
VWF:Ag on the same ELISA workstation, also as an in house sandwich
ELISA assay and essentially as previously extensively reported by our
laboratory (refer to [1,7,8,12] as key references), currently using bovine
collagen (reﬂecting a type I/III collagen mixture) from ICN Biomedicals
(catalogue no. 193492) for coating 96-well plates (Pierce Maleic Anhy-
dride activated plates; catalogueno. 15110; Thermo Scientiﬁc, Rockford,
USA) and Dako horse radish peroxidase labeled rabbit anti-humanVWF
(catalogue no. P0226) for VWF detection. Historically, a similar ap-
proach was used to perform manual/semi-automated ELISAs, but
using alternate ELISA plates (Linbro Titertek EIA plate; ICN Biomedicals,
Aurora, OH, USA). Our standard VWF:RCowas performed as an aggluti-
nation assay, essentially as also previously extensively reported by our
laboratory (refer to [1,7,8,12] as key references), currently on a CS-
5100 analyzer, using Siemens reagents (BC VWF reagent; catalogue
no. 10446425). Historically, we originally used in-house ﬁxed platelets
on a platelet aggregometer, and later the same systemwe currently em-
ploy but with testing performed on a Behring BCS analyzer. For the
Table 2
Summary of samples evaluated in this study.
Sample type Category/Abbreviation Total
Individual normal samples 13
‘Low VWF’ ‘pVWD-1’ 67
Type 1 VWD ‘VWD-1’ 20
Type 3 VWD ‘VWD-3’ 5
Type 2 VWD ‘VWD-2A’ + ‘pVWD-2A’ 24
‘VWD-2M’ + ‘pVWD-2M’ 8
‘VWD-2B’ 11
Platelet-type VWD ‘PT-VWD’ 3
Non-VWD cases⁎ 107
Other⁎⁎ 177
Totals 435
See Methods section for detail. This table excludes control samples (with control samples,
n = 535).
⁎ Cases that were assessed for VWF/VWD that were found not to have VWD following
laboratory testing.
⁎⁎ all other samples, including VWD post treatment with desmopressin (DDAVP) or
VWF concentrate, purpose generated HMW reduced test samples, platelet lysate samples,
and other miscellaneous test samples.
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cently performed, deﬁne the assay ‘reference’ methods, and they have
been previously validated for use in the identiﬁcation and preliminary
typing of VWD cases, as extensively reported by our laboratory (refer
to [1,7,8,12] as key references). These assays were performed by multi-
ple operators (n = 4) over the time of testing, according to the staff
member then on duty. Siemens Standard Human Plasma (catalogue
no. 10446238) was used as the calibrator for all three reference assays.
2.3. Evaluation methods
Themain test systems evaluated in this study comprised chemilumi-
nescent based VWF:Ag, VWF:RCo and VWF:CB assays performed on an
ACL AcuStar™ instrument (all from IL, Bedford, Ma. USA). The ACL
AcuStar is the latest addition to the IL family of hemostasis instruments
and represents advanced instrumentation using chemiluminescent
technology. Further information is available via the IL website (http://
www.instrumentationlaboratory.com/products-services/hemostasis-
diagnostics/instruments/acl-acustar.aspx). In speciﬁc detail, tests
employed were: (a) HemosIL AcuStar VWF:Ag (catalogue no. 0009802020;
lot B23919); (b) HemosIL AcuStar VWF:RCo (0009802024; lot B23891);
(c) HemosIL AcuStar VWF:CB (lot B23212). Each of these tests were per-
formed by a single operator (SM), usingmanufacturer provided protocols
for the ACL AcuStar and otherwise following manufacturer instructions.
The period of analysis comprised an approximate 4 month period in
2015. The VWF:Ag and VWF:RCo assays are already commercially avail-
able for use on the instrument. Both test systems utilize dedicated car-
tridges containing a vial of magnetic particle suspension. The VWF:Ag
test system employs rabbit anti-VWF polyclonal antibody bound to the
particles to capture plasma VWF, a particle separation and washing
step, addition of rabbit anti-VWF polyclonal antibody labeled with
Isoluminol, incubation and further washing, and ﬁnally triggers are
added to cause a chemiluminescent reaction that is measured by the in-
strument, and which is proportional to the level of VWF present in plas-
ma. The VWF:RCo test system employs magnetic particles coated with a
recombinant fragment of GPIb by means of a speciﬁc monoclonal anti-
body that orientates the fragment to permit binding of plasma VWF
mixedwith added ristocetin. The plasma VWF thus binds to themagnetic
particles in the presence of ristocetin, and following a particle separation
and washing step, an anti-VWF monoclonal antibody labeled with
Isoluminol is added, with incubation and more washing, and ﬁnally trig-
gers are added to cause a chemiluminescent reaction that is measured
by the instrument, and which is proportional to the level of VWF:RCo
present in plasma. The VWF:CB is not yet commercially released; we uti-
lized pre-releasematerial for the current evaluation, and no speciﬁc prod-
uct information was available, although in discussions with the
manufacturer, the assay uses similar assay steps to the VWF:Ag and
VWF:RCo assays, but employs a peptide fragment of type III collagen to
capture VWF onto the magnetic particles. For the purpose of the evalua-
tion, the manufacturer provided a loan ACL AcuStar instrument, and all
HemosIL AcuStar reagents and test controls free of cost to us, but did
not otherwise provide any other funding, nor otherwise inﬂuenced the
outcome of this evaluation.
An additional Siemens Innovance ‘VWF activity assay’, or ‘VWF Ac’,
representing a direct GPIb binding assay, and previously validated by
us and by others as representing a similar assay proﬁle to VWF:RCo
[12–15], was also included in this study for comparative evaluation
purposes.
2.4. Assay controls
We employed the following controls for this evaluation: (a) For the
VWF:Ag, VWF:CB and VWF:RCo reference methods and for VWF Ac,
plus all reference method activity/Ag ratios, we utilized several com-
mercial controls: (i) Dade Standard Human Plasma (DSHP) (Siemens)
as normal control, (ii) Coag A (Technoclone, Vienna, Austria) as ageneral pathological control, and (iii) VWF deﬁcient plasma (VWF DP)
Afﬁnity Diagnostics, Toronto, Canada) as an additional (type 3 VWD-
like) control. In addition, we also used an in-house control
(cryosupernatant; ‘Cryo’) as an additional type 2A VWD-like control.
(b) For the HemosIL AcuStar VWF assays, we utilized ILWerfen provid-
ed controls, namely (normal and pathological respectively): ‘Normal
Control Assayed’ and ‘Special test control level 2’ (for VWF:CB), Normal
VWF Cotrol (‘VWF N’) and Low VWF control (‘VWF L’) (for VWF:Ag and
VWF:RCo). As different IL Werfen controls were used for VWF:CB com-
pared to VWF:Ag and VWF:RCo, direct comparison of control data for
the three IL Werfen VWF assays is not possible, nor could we generate
CB/Ag activity data for these controls. As part of the evaluation process,
most controls were additionally tested on the alternate test systems
(i.e., HemosIL AcuStar controls were tested with reference assays and
reference assay controls were tested with HemosIL AcuStar assays), to
both assess potential additional utility of controls for the AcuStar test
system, aswell as to evaluate inter-assay variability (or reproducibility).
In summary, then, DSHP, Coag A, VWFDP and ‘Cryo’were assessed in all
assay systems, and permitted best cross comparability.
2.5. Study design and sample set for evaluation purposes
We employed a large total sample set (n= 535) for this evaluation,
hoping to maximize the evaluation given the limited quantity of
HemosIL AcuStar reagents available and to mimic as much as possible
the variety of material tested by VWD testing laboratories. Accordingly,
this sample set comprised various test materials (summarized in
Table 2) and including: (a) plasma and platelet-lysate samples from in-
dividualswith andwithout VWD; (b) someVWD samples frompatients
on treatment with either VWF concentrate (Biostate, CSL Ltd., Mel-
bourne Australia) [18,19] or desmopressin (DDAVP); (c) several sam-
ples from VWD patients undergoing DDAVP trials; (d) normal
plasmas; (e) normal and pathological commercial and in-house gener-
ated control plasmas; (f) a plasma sample set with increasing reduction
of HMWVWF to assess relative assay sensitivity. The lattermaterialwas
prepared using a proprietary process that has been partially previously
described [20].
2.6. VWD cases
This study comprised assessment of a large set of samples (n=138)
from patients identiﬁed to have VWD or possible VWD or plausible low
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and subsequent assessment with our standard (reference) test panels,
selectively supplemented as required by additional evaluation using
desmopressin trials, genetic testing and multimer analysis, as previous-
ly reported [4,5,8,21–24].
For the purpose of this report, VWD cases were phenotypically
identiﬁed as type 1 VWD (‘VWD-1’) when levels of VWF fell below
36 U/dL, but VWF activity assays showed concordance with
VWF:Ag (i.e., VWF:CB/VWF:Ag [CB/Ag] and VWF:RCo/VWF:Ag
[RCo/Ag] ratios were both above 0.7). The value of 36 U/dL was cho-
sen according to our local experience, but is similar to the cut-off of
30 U/dL chosen by Nichols et al. [10]. Activity/Ag ratios were not cal-
culated for type 1 VWD cases with VWF:Ag below 16 U/dL, due to
known issues with assay variability and use of small values in the
calculation, and since discrimination of these cases as type 1 vs 2 is
contentious. A separate group of patients with VWF:Ag results close
to the normal range cut-off value were identiﬁed as plausibly suffer-
ing from ‘low VWF’ [10] (as a risk factor for bleeding) when VWF:Ag
levels were between 36 and 65 U/dL (‘pVWD-1’), together with
VWF:CB and VWF:RCo concordance. VWD cases were identiﬁed as
type 3 (‘VWD-3’) when VWF:Ag levels were identiﬁed to be below
5 U/dL.
VWD cases were phenotypically deﬁned as type 2 when there was
evident discordance between VWF:Ag and VWF activity assays. Type
2N VWD cases were not included in this study since the investigated
VWF activity assays do not substantially contribute to their speciﬁc di-
agnosis (which requires either a VWF:FVIII binding assay and/or genetic
analysis). Type 2B VWD cases (‘VWD-2B’) were speciﬁcally identiﬁed
by heightened ristocetin induced platelet aggregation (RIPA) and this
was conﬁrmed where possible by genetic analysis (most cases). Most,
but not all, cases of 2B VWD also show functional VWF discordance
with CB/Ag and RCo/Ag below 0.7. Type 2A VWD cases (‘VWD-2A’)
were primarily characterized by functional VWF discordance with
both CB/Ag and RCo/Ag below 0.7, conﬁrmed by repeat testing, supple-
mented if available with data from desmopressin responsiveness and
multimer analysis, and conﬁrmed where possible by genetic analysis,
as previously reported [4,5,8,21–24]. Where conﬁrmation was not
possible, the term provisional 2A VWD is used (‘pVWD-2A’). Platelet
binding defect type 2MVWD cases (‘VWD-2M’) were primarily charac-
terized by functional VWF discordance with RCo/Ag below 0.7, but nor-
mal CB/Ag (N0.7), conﬁrmed by repeat testing, supplemented if
available with data from desmopressin responsiveness and multimer
analysis, and also conﬁrmed where possible by genetic analysis [4,5,8,
21–24]. Where conﬁrmation was not possible, the term provisional
2M VWD is used (‘pVWD-2M’).
This information is summarized in Table 2, which also details test
sample numbers.2.7. Desmopressin (DDAVP) response study
We also assessed several sets of desmopressin trial samples with all
assays, to again determine comparability. Thesewere mostly retrospec-
tively collected and stored samples, and comprised type 1 and type 2A
VWD cases.2.8. Data analysis
Data in this report is analysed largely using descriptive statistics, and
comparisons are primarily made using regression and Bland–Altman
analysis, using GraphPad Prism software (La Jolla, CA, USA). Some com-
parisonswere also performed for new ‘referencemethod’ data vs histor-
ical data, the latter reﬂecting the original test data obtained on the
samples prior to their storage and subsequent retrieval for the current
retrospective study.3. Results
3.1. Comparability of assay data
3.1.1. VWF:Ag
Data for VWF:Ag performed using the composite data set (all
samples in Table 2; n = 435) and the reference ELISA method vs the
chemiluminescent method on the ACL AcuStar is shown in Supplemen-
tary Fig. 1. Results were in general highly correlated (r = 0.9734), and
also largely comparable to historical VWF:Ag results (p = 0.9601;
Supplementary Fig. 1). Most data points were scattered around the
line of equivalence, although a few points fell outside expected limits.
As this occurred for both comparisons (i.e., ACL AcuStar and historical
VWF:Ag), this would most likely be due to random error events in the
majority of cases. There was also minimal bias, as evidenced by the
Bland-Altman plot (Supplementary Fig. 2 & B).
3.1.2. VWF:RCo
Data for VWF:RCo performed using the current reference method
(CS5100 analyzer) vs the test method (AcuStar) is shown in
Supplementary Fig. 1. Results were again, in general, highly correlated
(r = 0.9277), and largely comparable to historical VWF:RCo results
(p = 0.8854; Supplementary Fig. 1), as well as to the GPIb binding
assay (VWF Ac; p = 0.9415;Supplementary Fig. 1). However, for this
test, there was substantial bias evident for all assays (Supplementary
Fig. 2-E), comprising the VWF:RCo performed on the ACL AcuStar, the
historical VWF:RCo performed on BCS, and even the VWF Ac. Notably,
however, there was far less bias evident for the historical VWF:RCo per-
formed on BCS vs the AcuStar VWF:RCo and VWF Ac (Supplementary
Fig. 2 & G), suggesting the current CS-5100 VWF:RCo assay to be the
‘outlier’ of the ‘platelet GP-Ib binding assay’ group.
3.1.3. VWF:CB
Data for VWF:CB performed using the current reference method
(ELISA) vs the test method (AcuStar) is shown in Supplementary
Fig. 1. Results were again in general highly correlated (r = 0.9358),
and largely comparable to historical VWF:CB results (p = 0.9267;
Supplementary Fig. 1). Most data points were scattered around the
line of equivalence, although a few points fell outside expected limits.
As this occurred for both comparisons, for the majority of cases this
would most likely be due to random error events. There was also
minimal bias, as evidenced by the Bland-Altman plot (Supplementary
Fig. 2 & I). However, a few results did show substantial differences,
and these are detailed later.
3.1.4. Narrower VWD dataset comparisons
Theprevious ‘full’ data set analysis (n=435)was performed to get a
comprehensive picture of the comparative behavior of the different as-
says when used to test a wide battery of varied test material, as may
occur in normal test practice (Supplementary Figs. 1 and 2). In order
to get a better idea of comparative test performance with speciﬁc re-
spect to VWD diagnostics, some subset data analysis was undertaken
with a smaller data set comprising plasma samples from individuals
with and without VWD, but excluding high level VWF samples, and
also excluding other samples such as DDAVP, VWD treatment samples,
and platelet lysate samples. Themain linear regression data is shown in
Fig. 1. For VWF:Ag and VWF:RCo, the trend is similar to that of the ex-
tended data set. There was also a similar trend for the VWF:CB with re-
spect to the extended data set, but there were some noticeable outliers
for the HemosIL AcuStar VWF:CB (circled and arrowed in Fig. 1C). The
VWD dataset was further subanalysed and some representative data is
shown in Fig. 2. We observed a few instances of ‘assay failures’ (or
false positives, as well as false negatives) with all VWF test methodolo-
gies performed in this evaluation (Supplementary Table 1). In total, we
identiﬁed 11 potentially diagnostically important ‘assay failures’ for the
10 different assay systems employed, with this coming from a base of
Fig. 1. Comparative data for various assays for smaller more VWD diagnostically relevant
sample set assessed in this study (n=314), and shownby regression analysis, using study
reference method on x-axis, and comparative test data on y-axis. All data shown in U/dL.
The line of equivalence identiﬁes ‘referencemethod’ vs ‘referencemethod’ data. The linear
regression lines for each comparator method also shown with identiﬁed R value; lines
close to the line of equivalence reﬂect minimal bias of data. Panel A: VWF:Ag reference
method data (automated ELISA; E Ag) vs historical VWF:Ag ELISA data (HE Ag) and vs
AcuStar VWF:Ag (IL Ag). Panel B: VWF:RCo historical reference method data (automated
agglutination by BCS; H RCo) vs AcuStar VWF:RCo (IL RCo) and vs Innovance VWF Ac on
CS5100 (CS Ac). Panel C: VWF:CB reference method data (automated ELISA; E CB) vs his-
torical VWF:CB ELISA data (HE CB) and vs AcuStar VWF:CB (IL CB). For panel C, single
arrowed data point reﬂects a case of assay error for AcuStar VWF:CB (false low value)
thatwas normalized on repeat testing (see also Supplementary Table 1; case 1) and circled
data indicates other outlier data (refer to manuscript text and Fig. 2 for further detail).
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Fig. 1C was determined to be an example of an assay ‘failure’ (or false
‘positive’) for the IL VWF:CB, yielding a value of 3.9 U/mL in the ﬁrst
run, but 91 U/mL on repeat testing (see also Supplementary Table 1,
Case 1). Overall results for this patient sample were consistent with an
absence of VWD (all other assays including repeat testing generallyN90 U/mL). This is the only clear assay ‘failure’ we observed with the
IL Acustar VWF three test panel in our evaluation (Supplementary
Table 1). This needs to be considered in context, and we similarly ob-
served a few instances of similar ‘assay failures’with all VWF test meth-
odologies. One such assay failure for our ELISA VWF:CB is arrowed in
Fig. 2A and B (Case 11 in Supplementary Table 1), and all ‘assay failures’
identiﬁed in the current evaluation are summarized in Supplementary
Table 1. Potentially more interesting are discrepancies between
VWF:CB methodologies where HemosIL AcuStar VWF:CB values were
clearly lower than ELISA VWF:CB values (see circled data set in Fig. 1C,
which are also clearly identiﬁedwhen data is expressed as CB/Ag ratios;
Fig. 2A). These were invariably found to comprise samples from the
‘type 2 VWD sample set’ (Table 2), and type 2 VWD samples showed a
clear bias in test data for HemosIL AcuStar VWF:CB compared to the
ELISA method (Fig. 2B). This ﬁnding is further highlighted in Fig. 2C
and D, where the comparative data for the ‘Type 1 VWD data set’
(Fig. 2C) shows similar outcomes for all comparative methodologies
(i.e., VWF:Ag by different methods, VWF:RCo by different methods,
VWF:CB by different methods, as well as assay ratio comparisons),
whereas that for the ‘Type 2 VWD data set’ (Fig. 2D) shows a reduced
median and range for HemosIL AcuStar VWF:CB vs ELISA VWF:CB and
HemosiL Acustar CB/Ag vs ELISA CB/Ag. This differential suggests that
the HemosIL AcuStar VWF:CB is potentially more sensitive to type 2
VWD defects than the reference ELISA VWF:CB.
3.2. Desmopressin test data
Data for two representative patients, one type 1 VWD and the other
type 2A VWD, is shown in Fig. 3. Patients from the ‘type 1 VWD sample
set’ (n= 3) showed similar rises in all test parameters with VWF activ-
ity/antigen ratios above 0.5 at all time points, similar to the representa-
tive case in Fig. 3. In contrast, patients with type 2A VWD (n = 3)
showed good increments in VWF:Ag (both ELISA andAcuStar), butmin-
imal increments in all VWF activity assays, and VWF activity/antigen ra-
tios remained below 0.5 at all time points, similar to the representative
case in Fig. 3. Therewas no clear discrepant pattern observable between
comparable methodologies – thus, ELISA and HemsoIL AcuStar VWF:Ag
behaved similarly, all VWF:RComethodologies and the Innovance VWF
Ac assays behave similarly, and both VWF:CB methods (ELISA and
AcuStar) also behaved similarly. Given the expected release of HMW
VWF post DDAVP in type 1 VWD, VWF activity assays would be expect-
ed to increment more than VWF:Ag, as would also be reﬂected by VWF
activity/Ag ratios. Interestingly, then, although ‘type 2 VWD data set’
suggested increased discriminatory sensitivity of the HemsoIL AcuStar
VWF:CB/Ag ratio for type 2 vs type 1 VWD (Fig. 2), this did not seem
to translate into universally heightened sensitivity for the HemsoIL
AcuStar VWF:CB/Ag ratio compared to ELISA VWF:CB, or VWF:RCo or
RCo/Ag ratios for that matter, in the DDAVP data (Fig. 3).
3.3. Differential sensitivity to loss of HMW VWF
Using a set of four samples with step-wise reduction in HMW VWF,
VWF:Ag values were determined to remain within normal levels,
although the HemsoIL AcuStar VWF:Ag method did show a fall with in-
creasing HMW VWF reduction (Fig. 4). All VWF activity assays showed
much larger sequential falls in values. There was a suggestion that the
HemosIL AcuStar VWF:CB and thus CB/Ag ratios were quite responsive
in this analysis, but interpretation is complicated by the sequential fall
in HemsoIL AcuStar VWF:Ag.
3.4. Differentials in VWD identiﬁcation/diagnosis
An assessment was undertaken of the differential in identiﬁcation
and preliminary classiﬁcation of VWD type (should VWD have been
suggestive of preliminary testing). There were occasional discrepancies
between the local reference assays and test panel, versus the original
Fig. 2. Evaluation of discordant data set for VWF:CB assays. Panel A. Regression analysis for VWF:CB/VWF:Ag (CB/Ag) ratios for the smaller more VWD diagnostically relevant sample set
assessed in this study (n= 314) using data from Fig. 1A and C. The single arrowed data point reﬂects a case of assay error for historical CB/Ag (false normal ratio) that was correctly iden-
tiﬁed as low on repeat testing (see also Supplementary Table 1; case 11) and circled data indicates outlier data that is further identiﬁed in subsequent Fig. 2 panels. Panel B. Same regression
analysis as per Panel A, but data set restricted to type 2 VWD data set (comprising all cases of type 2A, 2B, 2M and PT VWD, as well as provisional type 2A and 2M cases; see Table 2).
The single arrowed data point reﬂects the same case of assay error as for Panel A. Note the clear bias in test results for AcuStar CB/Ag for this data set. Panel C. Data for VWF:CB and
VWF:CB/VWF:Ag (CB/Ag) for ‘type 1 VWD data set’ (refer to Table 2; comprising all low VWF and type 1 VWDwith VWF:Ag above 15 U/dL). Error bars identify median and interquartile
ranges. Panel D. Data for VWF:CB and VWF:CB/VWF:Ag (CB/Ag) for ‘type 2 VWD data set’ from Panel B. Error bars identify median and interquartile ranges. Assay abbreviations: E CB=
reference VWF:CB by ELISA; HE CB= historical VWF:CB by ELISA; IL CB= AcuStar VWF:CB; E CB/Ag= reference VWF:CB/VWF:Ag by ELISA; HE CB/Ag= historical VWF:CB/VWF:Ag by
ELISA; IL CB/Ag = AcuStar VWF:CB/VWF:Ag.
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resented minor discrepancies, proposed to be due primarily to test re-
sult variation (random error events), and for example: (i) normal
samples with values close to normal/abnormal cut-off values gave
values within the normal range on occasion and values just below the
normal range on other occasions, and thus samples would be identiﬁed
as normal on some occasions, and possible ‘low VWF’ (‘pVWD-1’) on
other occasions; (ii) samples given a provisional interpretation of ‘low
VWF’ (‘pVWD-1’, or type 1 VWD (‘VWD-1’), on one occasion might
also be given the alternate interpretation based on movements of test
values around the cut-off values (as deﬁned in the Methods section).
Also, samples given a provisional interpretation as possible type 2M
(‘pVWD-2M’) or possible 2A VWD (‘pVWD-2A’) based on activity/
antigen discordance using some test panels were occasionally given
the alternate provisional interpretation based on similar (usually
small) movements in test values. In all the above cases, standard
operating procedures, including repeat testing using a fresh sample on
another occasion, or conﬁrmatory and extended testingusing additional
test procedures, would have provided clarity of the provisional diagno-
sis. However, there was clear discrepancy in ﬁndings using the HemosIL
AcuStar VWF test panel for those samples provisionally identiﬁed as
platelet GPIb binding defect type 2M VWD by differential testing of
BCS or CS5100 VWF:RCo or VWF Ac and VWF:CB by ELISA, withresultant low RCo/Ag and Ac/Ag ratios, but normal CB/Ag ratios by the
reference methods; many of these samples would be identiﬁed as ‘2A
VWD-like’ using the HemosIL AcuStar VWF test panel (i.e., yielding
low RCo/Ag plus low CB/Ag ratio). Of interest, however, one well char-
acterized 2M case was clearly identiﬁed as 2M by the HemsoIL AcuStar
VWF test panel.
3.5. Assay variability
We assessed inter-assay reproducibility in this study using several
control samples. This evaluation also helped to assess potential added
utility of non-kit controls to kit provided controls. Data is summarized
in Table 3, and select data shown in Fig. 5. The HemosIL AcuStar VWF
methodology clearly yielded the best reproducibility (lowest inter-
assay variation) for all AcuStar VWF assays compared to all other com-
parator assays, particularly when using the IL provided assay controls.
3.6. Low level VWF sensitivity
We also assessed low level VWF sensitivity using a VWF deﬁcient
plasma control, plus samples from patients with type 3 VWD. Data is
shown in Fig. 5. The AcuStar VWF methodology clearly yielded the
best low limit of VWF sensitivity for all AcuStar VWF assays compared
Fig. 3. Data for representative VWD patients for desmopressin (DDAVP) responses using
different assays evaluated in this study. X-axis in each case reﬂects time-point of sample
collection pre (‘0’ time) and post (in hours) desmopressin; left y-axis in each case iden-
tiﬁes VWF level in U/dL, and right y-axis various VWF activity to antigen ratios. Panel A:
representative patient with type 1 VWD/‘low VWF’ (‘pVWD-1’) (refer to Table 2). Panel
B: representative patient with type 2A VWD. Assay abbreviations: E Ag = reference
VWF:Ag by ELISA; E CB = reference VWF:CB by ELISA; CS RCo = reference VWF:RCo by
agglutination on CS5100; HE Ag = historical VWF:Ag by ELISA; HE CB = historical
VWF:CB by ELISA; H RCo = historical VWF:RCo by agglutination; IL Ag = AcuStar
VWF:Ag; IL CB = AcuStar VWF:CB; IL RCo = AcuStar VWF:RCo; CS Ac = Siemens
Innovance VWF ‘activity’ on CS5100; E CB/Ag = reference VWF:CB/VWF:Ag by ELISA;
CS RCo/Ag = reference VWF:RCo/VWF:Ag; HE CB/Ag = historical VWF:CB/VWF:Ag; H
RCo/Ag = historical VWF:RcCo/VWF:Ag; IL CB/Ag = AcuStar VWF:CB/VWF:Ag; IL RCo/
Ag = AcuStar VWF:RCo/VWF:Ag; CS Ac/Ag = Siemens Innovance VWF ‘activity’ on
CS5100/VWF:Ag by reference ELISA.
Fig. 4. Assay data using a set of four samples showing step-wise reduction in high molec-
ularweight (HMW)VWF from a pool of normal plasma (PNP), with each subsequent sam-
ple (HMWRED ↓, HMWRED ↓↓ and HMWRED ↓↓↓) expressing a reduction of ~25%, ~50%
and ~75% of the HMWVWFmultimers. Assay data, with VWF values using different assay
procedures shown on left y-axis in U/dL, and various VWF activity/VWF:Ag assay ratios
shown on right y-axis. Assay abbreviations as per Fig. 3.
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consistently reported b1 U/mL for all tests on these samples except one
patient type 3 VWD sample (HemosIL AcuStar VWF:Ag = 1.8 U/mL),
who is already known by us to express a trace amount of VWF:Ag,
giving values consistently just above that of VWF deﬁcient plasma
when tested by ELISA VWF:Ag on many occasions in the past.
4. Discussion
In this study, a large number of overall test samples (n = 535; n =
435 excluding controls) of diverse nature have been cross-tested using
a variety of VWF assays (Table 1), but primarily aiming to evaluate
a reasonably new addition to the hemostasis armamentarium, the
chemiluminescent-based ACL AcuStar, and an associated chemilumi-
nescent three VWF test panel comprising HemosIL AcuStar VWF:Ag,
HemosIL AcuStar VWF:RCo and HemosIL AcuStar VWF:CB. The aim of
using the overall diverse sample set was to ‘mimic’ what occurs in real
world test practice, as well as to maximize the evaluation given the
limited availability of HemosIL AcuStar VWF test reagents. There
was a high level of concordance between VWF assays performed using
our standard (reference) methods versus comparator VWF assays(Supplementary Fig. 1). Thus, VWF:Ag using the reference ELISA meth-
od yielded good comparability to HemosIL AcuStar VWF:Ag, VWF:RCo
by agglutination yielded good comparability to HemosIL AcuStar
VWF:RCo (and Innovance VWF Ac), and VWF:CB using the reference
ELISA method yielded good comparability to HemosIL AcuStar
VWF:CB. There was also little bias in test results for comparator VWF
assays, except for VWF:RCo, where analysis suggested that the current
agglutination method on the CS-5100, used as reference in this
study, actually represented the outlier assay of the group, and less bias
was observed between the other VWF:RCo and VWF:Ac methods
(Supplementary Fig. 2). In general, similar ﬁndings were evident
when the analysis was limited to a smaller more VWD diagnostics rele-
vant sample set (Fig. 1).
Most of the scatter in regression and Bland-Altman plots is likely to
simply reﬂect assay variation (random error) events, given that similar
scatter was seen between the historical test data and repeat testing
using similar methodologies. Occasional outliers reﬂect an alternate ex-
planation. Several signiﬁcant outliers (examples arrowed in Figs. 1 and
2) reﬂected occasional false positive and false negative events (summa-
rized in Supplementary Table 1), which occurred for all methods. This
was evidenced by repeat testing or by ‘consensus test ﬁndings’, which
then more clearly identiﬁed the true test pattern. This is consistent
with the known limitations of VWF testing, and simply identiﬁes that
occasional errors will occur with all methodologies, as well as helping
to justify the need for repeat testing in VWD diagnostics to conﬁrm ini-
tial test ﬁndings. Importantly, only a few such events actually occurred
during this evaluation (total of 11 potentially diagnostically important
failures from over 5000 different test events), and the ACL AcuStar
system seemed to represent the most robust of the systems evaluated,
with only a single such event.
Some variation in test data between HemosIL AcuStar and ELISA
VWF:CB methods was also evident, but this was restricted to the ‘type
2-VWD sample set’, and generally expressed as lower VWF:CB values
for the AcuStar method, with correspondingly lower HemosIL AcuStar
CB/Ag ratios also evident. This suggests better sensitivity of theHemosIL
AcuStar VWF:CB method to type 2 VWF mutations and possibly also
better HMW sensitivity compared to the ELISA VWF:CB method. This
ﬁnding is currently the subject of further investigation by us. The
HemosIL AcuStar VWF:CB has not yet been released to market, and
our evaluation was that of a pre-market release. There was no product
insert available in the pre-release material, but advice from the manu-
facturer indicates that the ‘collagen’ used in the test system is actually
Table 3
Summary of inter-assay variability for different assays*.
Sample IL Ag IL CB IL RCo IL CB/Ag IL RCo/Ag CS RCo CS Ac CS RCo/E Ag CS Ac/E Ag E Ag E CB CB/Ag
COAG A
Mean 46.3 26.3 32.8 0.6 0.7 24.0 29.1 0.5 0.6 46.8 38.6 0.8
Median 45.5 25.9 31.3 0.6 0.7 25.3 29.0 0.5 0.6 46.0 38.5 0.8
CV% 8.4 14.8 11.5 11.4 4.4 19.9 13.6 20.1 9.2 7.9 13.1 9.0
CRYO
Mean 18.0 5.3 7.2 0.3 0.4 11.5 5.9 0.5 0.3 22.4 10.1 0.5
Median 18.0 5.3 7.6 0.3 0.4 10.8 6.1 0.5 0.3 23.0 10.0 0.5
CV% 2.6 22.6 16.9 22.0 16.0 31.9 16.2 37.9 22.7 10.2 19.3 17.9
DSHP
Mean 100.1 98.9 90.3 1.0 0.9 103.7 95.2 1.1 1.0 98.9 98.4 1.0
Median 99.5 99.0 90.8 1.0 0.9 106.6 94.4 1.1 1.0 99.5 99.5 1.0
CV% 4.6 3.8 4.2 6.7 5.1 10.7 2.9 13.0 4.9 6.0 7.2 5.9
IL CB Low
Mean – 18.4 – – – 19.3 18.5 0.9 0.8 22.4 21.4 1.0
Median – 18.3 – – – 18.5 18.0 0.9 0.8 23.0 22.0 1.0
CV% – 5.0 – – – 17.0 8.8 16.9 11.1 9.2 14.0 13.7
IL CB Nor
Mean – 79.2 – – – 80.6 81.5 0.8 0.8 103.2 105.3 1.0
Median – 79.2 – – – 78.5 82.5 0.8 0.8 104.0 107.0 1.0
CV% – 4.9 – – – 12.2 6.1 10.6 8.9 7.4 12.6 11.8
IL VWF Low
Mean 31.4 - 26.2 – – 23.8 26.6 0.8 0.9 30.6 29.3 1.0
Median 31.7 - 26.0 – – 21.0 25.5 0.7 0.9 30.0 29.0 1.0
CV% 3.7 - 2.6 – – 46.3 20.3 41.0 18.9 5.6 13.6 13.4
IL VWF Nor
Mean 96.2 – 85.9 – – 66.7 77.3 0.7 0.8 95.1 98.3 1.0
Median 97.1 – 84.8 – – 70.0 77.0 0.7 0.8 97.0 96.0 1.0
CV% 6.8 – 9.6 – – 15.7 9.8 17.6 15.5 8.7 12.5 11.2
VWF Def
Mean 0.2 0.0 0.3 – – 1.5 0.8 – – 1.0 2.1 –
Median 0.2 0.0 0.4 – – 0.0 0.0 – – 1.0 2.0 –
Abbreviations: VWF, von Willebrand factor; Ag, antigen; RCo, ristocetin cofactor; CB, collagen binding; Ac, activity; IL, IL Werfen AcuStar; CS, CS5100; E, ELISA.
Data shown as coefﬁcient of variation (CV, %), using control plasmas cross tested in different assay systems. CV% and ratios not calculated for VWF deﬁcient plasma.
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GPRGQOGVMGFO-(GPP)5-GPCNH2), as based on the work of Lisman
and Farndale and colleagues [25–27], whereas our reference VWF:CB
employs a commercial bovine collagen source reﬂecting a type I/type
III collagen mixture. We would therefore hypothesize that this could
easily explain a higher sensitivity to type 2 VWF mutational changes
using the HemosIL AcuStar VWF:CB assay.
Also evident in our study was the excellent reproducibility (Fig. 5,
Table 3) of the AcuStar VWF test panel (for each assay, VWF:Ag,
VWF:RCo and VWF:CB), in addition to excellent low level VWF sensitiv-
ity for each of these assays (Fig. 5), whichwere all capable of consistent-
ly detecting VWF down to b1U/dL. In contrast, all other VWFassays had
higher variability and poorer sensitivity to low levels of VWF, which oc-
casionally reached below 1 U/mL, but was more often between 1 and
5 U/mL.
There have been previously published evaluations of the ACL
AcuStar chemiluminescent assay system, including that for VWF:Ag
and VWF:RCo [28–32]. However, to our knowledge, our study is the
ﬁrst ever independent evaluation of the HemosIL AcuStar VWF:CB, as
well as the ﬁrst ever evaluation of the comprehensive three
chemiluminescent-based VWF test panel set, the ﬁrst ever evaluation
of such a three test panel (VWF:Ag, VWF:RCo, VWF:CB) available on a
single analyzer, and also the ﬁrst side to side evaluation of these
chemiluminescent-based assays with the Innovance VWF Ac assay. In
previous VWF AcuStar evaluations, only VWF:Ag and VWF:RCo assays
have been evaluated, as follows: (i) Verfaillie et al. evaluated the
HemosIL VWF:Ag and VWF:RCo assays compared to VWF:Ag by LIA
and VWF:RCo by aggregometry and reported good agreement between
evaluation and reference methods, further concluding that HemosIL as-
says were more sensitive to VWD; (ii) de Maistre et al. compared theHemosIL AcuStar VWF:RCo against a reference VWF:RCo by agglutina-
tion as well as the Innovance VWF Ac assay. They reported good corre-
lation and concordance between assays, and that both the HemosIL
AcuStar VWF:RCo and InnovanceVWFAc could replace VWF:RCo by ag-
glutinationwith additional beneﬁts of being fully automated, easier and
faster to perform, and better adapted to emergency use if required. (iii)
Costa-Pinto et al. compared HemosIL AcuStar VWF:Ag and VWF:RCo
with conventional methods, with concordance in VWD diagnosis in
most cases, with many of the disparities attributed to poorer perfor-
mance of conventional methodology. (iv) Stufano and colleagues com-
pared HemosIL AcuStar VWF:Ag and VWF:RCo against VWF:Ag and
VWF:RCo assays performed using immunoturbimetric (LIA-based) pro-
cedures on an ACL TOP 500. Again, therewasmostly concordance of pa-
tient VWD identiﬁcation, with only a few inconsistencies. The ACL
AcuStar was also identiﬁed to have a lower limit of VWF detection
than the LIA methods. (v) Finally, Cabera et al. also compared HemosIL
AcuStar VWF:RCo to a conventional VWF:RComethod, with good com-
parability in evidence.
There are several limitations to our study that can be identiﬁed. First,
this study was conceived as a comparative study for the purpose of po-
tential utility to identify and provisionally type VWD, as well as assess
responsiveness to VWD therapy. Accordingly, the evaluation did not en-
tail additional comprehensive testing of all potential VWD cases includ-
ing genetic testing. Nevertheless, the main differential diagnostic
ﬁndings in this studywere (i) that the ACL AcuStar test system, incorpo-
rating both VWF:RCo and VWF:CB, seemed better able to differentially
identify type 2 VWD from type 1 VWD compared to the reference and
other VWF test systems, and (ii) that a few cases reﬂecting potential
platelet binding defect type 2MVWD (according to reference methods)
yielded VWD2A-like ﬁndings in the case of the AcuStar test system. The
Fig. 5.Data for select control samples used to identify inter-assay reproducibility (Panels A-C) and for type 3 VWD samples assessed in this study (Panel D). VWF values using different assay
procedures shown on left y-axis in U/dL, and various VWF activity/VWF:Ag assay ratios shown on right y-axis for panels A and B. Assay abbreviations as per Fig. 3. Refer also to Table 3.
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tant, whereas the latter differential is more academic in nature; al-
though such differences (type 2A vs 2M VWD) can be resolved in
normal test practice by additional testingusingmultimer analysis, treat-
mentwould be identical in both cases (typically VWF concentrate). If 2B
VWD or platelet type VWD was instead suspected, this could be easily
resolved using RIPA analysis.
In conclusion, we report on a large comparative evaluation of
HemosIL AcuStar VWF:Ag, VWF:RCo and VWF:CB against our reference
methods (VWF:Ag and VWF:CB by ELISA; VWF:RCo by automated ag-
glutination) as well as against Innovance VWF Ac, using a wide variety
of material including cases of VWD and some cases undergoing treat-
ment. The ACL AcuStar tests showed the highest sensitivity to low levels
of VWF for all three HemosIL AcuStar, compared to all comparator, as-
says. This will be important in identiﬁcation of type 3 VWD as well as
in the discrimination of type 1 and 2 VWD. All the ACL AcuStar VWF
tests also showed the best assay reproducibility compared to all com-
parator assays, and this in part would help the test system to be more
robust andminimize diagnostic errors; thus, the greater degree of errors
identiﬁed within comparator assay systems (Supplementary Table 1)
likely relate, at least in part, to higher assay variability. Finally, the ACL
Acustar VWF tests showed good comparability with referencemethods,
validating these assays for use in both identifying VWD and for
desmopressin trials. The differential ﬁndings between the HemosIL
Acustar and reference method VWF:CB in regards to better sensitivity
to type 2 VWD defects (vs type 1 VWD), albeit with potentially lower
discriminatory differential between 2A and 2MVWD, is now the subject
of a more focused study.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.thromres.2015.12.010.
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